Standout Papers

New Guidelines to Evaluate the Response to Treatment in Solid Tumors 2000 2026 2008 2017 13.4k
  1. New Guidelines to Evaluate the Response to Treatment in Solid Tumors (2000)
    Patrick Therasse, Susan G. Arbuck et al. JNCI Journal of the National Cancer Institute
  2. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial (2006)
    George D. Demetri, Allan T. van Oosterom et al. The Lancet
  3. Cremophor EL (2001)
    Hans Gelderblom, Jaap Verweij et al. European Journal of Cancer
  4. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial (2004)
    Jaap Verweij, Paolo G. Casali et al. The Lancet
  5. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study (2001)
    Allan T. van Oosterom, Ian Judson et al. The Lancet
  6. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial (2014)
    Ian Judson, Jaap Verweij et al. The Lancet Oncology
  7. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours (2006)
    Maria Dêbiec‐Rychter, Raf Sciot et al. European Journal of Cancer
  8. Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas (2009)
    Isabelle Ray‐Coquard, Claire Cropet et al. Cancer Research
  9. Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors (2011)
    Johanna C. Bendell, Jordi Rodón et al. Journal of Clinical Oncology
  10. Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043) (2009)
    Stefan Sleijfer, Isabelle Ray‐Coquard et al. Journal of Clinical Oncology
  11. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study (2010)
    Rolf D. Issels, Lars H. Lindner et al. The Lancet Oncology
  12. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial (2012)
    Penella J. Woll, Peter Reichardt et al. The Lancet Oncology

Immediate Impact

2 by Nobel laureates 10 from Science/Nature 136 standout
Sub-graph 1 of 17

Citing Papers

Suppression of insulin feedback enhances the efficacy of PI3K inhibitors
2018 StandoutNature
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
2016 StandoutNobel
17 intermediate papers

Works of Jaap Verweij being referenced

Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
2011 Standout
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
2000 Standout

Author Peers

Author Last Decade Papers Cites
Jaap Verweij 27869 13557 21972 619 54.4k
David Cunningham 41215 12483 30035 1.2k 76.0k
Mithat Gönen 25916 7851 18942 769 58.9k
Cornelis J.�H. van de Velde 26904 5111 14055 684 46.7k
Jean‐Yves Blay 18978 5361 25741 1.2k 43.9k
Heikki Joensuu 12609 8283 11879 570 34.2k
Yung‐Jue Bang 20426 10595 16587 602 36.1k
Yoshihiko Maehara 13290 11091 12048 1.7k 42.1k
Josep Tabernero 33324 14088 14187 1.1k 49.1k
George D. Demetri 10951 6557 23206 342 37.2k
Markus W. Büchler 35999 11097 14320 1.1k 55.0k

All Works

Loading papers...

Rankless by CCL
2026